Sign In
Buy SPHDF
$23.25
+0 (+0%)
At Close: Jun 03, 2026
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript
02:57pm, Monday, 29'th Sep 2025
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Q2 2025 Earnings Call September 23, 2025 8:00 AM EDT Company Participants Catherine Isted - Chief Financial Officer Shabir Hasham - Chief Medical Offi
Santhera Pharmaceuticals Holding AG: Santhera''s Shareholders Approve all Board Proposals at Today''s Extraordinary General Meeting
12:29pm, Wednesday, 15'th Dec 2021 FinanzNachrichten
Pratteln, Switzerland, December 15, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Extraordinary General Me
Santhera Pharmaceuticals Holding AG: Santhera to Host Investor Conference Call - Looking Ahead to 2022
06:05am, Monday, 06'th Dec 2021 FinanzNachrichten
Pratteln, Switzerland, December 6, 2021 - Santhera Pharmaceuticals (SIX: SANN) is pleased to invite investors, shareholders, media representatives and interested parties to join a conference call o
Santhera to Host Investor Conference Call Looking Ahead to 2022
06:00am, Monday, 06'th Dec 2021 Intrado Digital Media
Pratteln, Switzerland, December 6 , 202 1 Santhera Pharmaceuticals (SIX: SANN) is pleased to invite investors, shareholders , media representatives and interested parties to join a conference call on December 8, 2021 at 1 5 :00 CET . In a moderated session, senior executives from Santhera will reflect on recent developments and discuss upcoming milestones as well as expectations ahead of 2022.
Santhera Pharmaceuticals Holding AG: Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Approval for Further Financings
06:05am, Wednesday, 24'th Nov 2021 FinanzNachrichten
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 24, 2021 - Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary Gener
Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchenne Muscular Dystrophy
06:05am, Wednesday, 17'th Nov 2021 FinanzNachrichten
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, November 17, 2021 -Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma (US: private) announce the
